WANY
ADMA icon

Wealthspire Advisors (New York)’s ADMA Biologics ADMA Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-248
Closed -$3.64K – 1057
2025
Q3 		$3.64K Buy
+248
New +$4.25K ﹤0.01% 2442

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Wealthspire Advisors (New York)'s ADMA Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 248 shares — an estimated $3.64K sold.

Wealthspire Advisors (New York) first reported a position in ADMA in Q3 2025 and held it in 1 quarter. The position peaked at $3.64K in Q3 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 248 ADMA Biologics shares in Q4 2025, an estimated $3.64K.
  • Wealthspire Advisors (New York) first reported a position in ADMA Biologics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s ADMA Biologics position peaked at $3.64K in Q3 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.